Literature DB >> 8174072

Clonal chromosome abnormalities in 54 cases of ovarian carcinoma.

F H Thompson1, J Emerson, D Alberts, Y Liu, X Y Guan, A Burgess, S Fox, R Taetle, R Weinstein, R Makar.   

Abstract

As a prelude to assessing the relationship of chromosome alterations to clinical outcome in ovarian carcinoma, we report on the cytogenetic analysis on short-term cultures from 54 patients. All patients had histopathologically confirmed malignancy, with the majority of cases demonstrating serous ovarian adenocarcinomas. Structural alterations were evident in 52 cases, whereas numeric changes were identified in 13 cases. The most notable numeric abnormalities were loss of the X-chromosome (9/13 total cases) and +7 (3/9 diploid cases). Structural alterations most frequently involved chromosomes 1, 3, 6, 7, 11, and 12. Chromosomal breakpoints were shown to cluster in several chromosomal banding regions, including 1p36, 1p11-q21, 3p23-p10, 7p (especially 7p22), 11p, 11q, 12p13-q12, and 12q24. The frequency of structural alterations involving the following chromosome arms was found to be significantly increased: 1p (p < 0.01), 7p (p < 0.01), 11p (p < 0.01), 11q (p < 0.05), and 12p (p < 0.05). An analysis of the net gain or loss of chromosome segments was also performed, with the most consistent tendency observed being over-representation of 1q and chromosome 7, deletion of 1p, and loss of the X chromosome.

Entities:  

Mesh:

Year:  1994        PMID: 8174072     DOI: 10.1016/0165-4608(94)90179-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.

Authors:  R Wu; D C Connolly; X Ren; E R Fearon; K R Cho
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components.

Authors:  N G Wolf; F W Abdul-Karim; N J Schork; S Schwartz
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

3.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

4.  Involvement of chromosome 6 in endometrial cancer.

Authors:  M G Tibiletti; B Bernasconi; M Taborelli; D Furlan; A Fabbri; M Franchi; R Taramelli; M Trubia; C Capella
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Evaluation of FHIT gene alterations in ovarian cancer.

Authors:  F Buttitta; A Marchetti; O Radi; G Bertacca; S Pellegrini; A Gadducci; A R Genazzani; G Bevilacqua
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

Review 6.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

7.  Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Vera M Abeler; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Oncol       Date:  2009-09-15       Impact factor: 4.375

8.  Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas.

Authors:  A Viel; L Dall'Agnese; F Simone; V Canzonieri; E Capozzi; M C Visentin; R Valle; M Boiocchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Allelic imbalance of chromosome 6q in ovarian tumours.

Authors:  V Orphanos; G McGown; Y Hey; M Thorncroft; M Santibanez-Koref; S E Russell; I Hickey; R J Atkinson; J M Boyle
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

10.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers.

Authors:  D J Brooks; S Woodward; F H Thompson; B Dos Santos; M Russell; J M Yang; X Y Guan; J Trent; D S Alberts; R Taetle
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.